Loading the company…
Loading the company…
In the last ten years FDA made 5 decisions for Lumendi (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2021 (2). The latest was on 2023-02-10.
| Family | Decisions on record |
|---|---|
| Colonoscopy & upper endoscopy | 6 |
In 2025, Lumendi reported engagement with 57 surgeons and other clinicians in the states MedaRep covers, worth $73K in consulting, speaking, meals and travel for its device products, the most in Ohio ($30K to 1). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Ohio ($30K, 1 engaged), Maryland ($30K, 1 engaged), Indiana ($5,992, 11 engaged), Pennsylvania ($2,792, 3 engaged), Texas ($1,108, 7 engaged).
| DiLumen C2; DiLumen Tool Mount |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Lumendi.